Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer

Overview

Journal Target Oncol

Specialty Oncology

Date 2019 Jul 24

PMID 31332693

Citations 4

Authors

Y Louise Wan

Puja Sapra

James Bolton

Jia Xin Chua

Lindy G Durrant

Peter L Stern

Affiliations

Soon will be listed here.

Abstract

Background: Recurrence occurs in over 75% of women with epithelial ovarian cancer despite optimal treatment. Selectively killing tumour cells thought to initiate relapse using an antibody-drug conjugate could prolong progression-free survival and offer an improved side-effect profile. A1mcMMAF is an antibody-drug conjugate designed to target cells expressing the tumour-associated antigen 5T4. It has shown to be efficacious in various cell line models and have a greater impact when combined with routine chemotherapeutic regimes.

Objectives: This study aims to explore the potential for the use of a 5T4 antibody-drug conjugate in women with ovarian cancer both as a monotherapy and in combination with platinum-based chemotherapy.

Methods: Immunohistochemical analysis was used to assess 5T4 expression in tumours from patients with ovarian cancer. Effectiveness of A1mcMMAF therapy as a single agent and in combination with carboplatin was assessed in vitro in the ovarian cancer cell line SKOV3 and confirmed in vivo using a serial bioluminescence assay in a SKOV3 xenograft model of ovarian cancer.

Results: 5T4 is confirmed as suitably expressed in epithelial ovarian cancers prior to adjuvant therapy and is an independent predictor of poor survival. A1mcMMAF showed specific activity, both in vitro and in vivo, against SKOV3 ovarian cancer cells. When used in combination with carboplatin, in vivo tumour growth was inhibited resulting in prolonged survival in a SKOV3 xenograft model.

Conclusions: These data support further investigation of A1mcMMAF in combination with platinum-based chemotherapy in ovarian and other cancer treatments.

Citing Articles

Therapeutic development targeting host heparan sulfate proteoglycan in SARS-CoV-2 infection.

Zhang Q, Pavlinov I, Ye Y, Zheng W Front Med (Lausanne). 2024; 11:1364657.

PMID: 38618194 PMC: 11014733. DOI: 10.3389/fmed.2024.1364657.

The Evolving Landscape of Antibody-Drug Conjugates: In Depth Analysis of Recent Research Progress.

Sasso J, Tenchov R, Bird R, Iyer K, Ralhan K, Rodriguez Y Bioconjug Chem. 2023; 34(11):1951-2000.

PMID: 37821099 PMC: 10655051. DOI: 10.1021/acs.bioconjchem.3c00374.

Combination of T-DM1 and platinum-based chemotherapy in patient-derived xenograft models of muscle-invasive bladder cancer.

Razzaghdoust A, Muhammadnejad S, Parvin M, Bahram B, Zangeneh M, Basiri A Iran J Basic Med Sci. 2022; 25(7):816-821.

PMID: 36033955 PMC: 9392562. DOI: 10.22038/IJBMS.2022.63509.14005.

Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment.

Terlikowska K, Dobrzycka B, Terlikowski S Int J Mol Sci. 2021; 22(7).

PMID: 33800608 PMC: 8037934. DOI: 10.3390/ijms22073495.

References

Shor B, Kahler J, Dougher M, Xu J, Mack M, Rosfjord E . Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes. Clin Cancer Res. 2015; 22(2):383-94. DOI: 10.1158/1078-0432.CCR-15-1166. View

Southall P, Boxer G, Bagshawe K, Hole N, Bromley M, Stern P . Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer. 1990; 61(1):89-95. PMC: 1971328. DOI: 10.1038/bjc.1990.20. View

Amato R, Drury N, Naylor S, Jac J, Saxena S, Cao A . Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother. 2008; 31(6):577-85. DOI: 10.1097/CJI.0b013e31817deafd. View

Stern P, Brazzatti J, Sawan S, McGinn O . Understanding and exploiting 5T4 oncofoetal glycoprotein expression. Semin Cancer Biol. 2014; 29:13-20. DOI: 10.1016/j.semcancer.2014.07.004. View

McCann K . Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer. Curr Opin Obstet Gynecol. 2017; 30(1):7-16. DOI: 10.1097/GCO.0000000000000428. View

Hawkins R, Macdermott C, Shablak A, Hamer C, Thistlethwaite F, Drury N . Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother. 2009; 32(4):424-9. DOI: 10.1097/CJI.0b013e31819d297e. View

Shah D, King L, Han X, Wentland J, Zhang Y, Lucas J . A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate. AAPS J. 2014; 16(3):452-63. PMC: 4012047. DOI: 10.1208/s12248-014-9576-9. View

Hoppenot C, Eckert M, Tienda S, Lengyel E . Who are the long-term survivors of high grade serous ovarian cancer?. Gynecol Oncol. 2017; 148(1):204-212. DOI: 10.1016/j.ygyno.2017.10.032. View

Castro F, McGinn O, Krishnan S, Marinov G, Li J, Rutkowski A . 5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype. Leukemia. 2012; 26(7):1487-98. PMC: 3378689. DOI: 10.1038/leu.2012.18. View

10.

Webb P, Jordan S . Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2016; 41:3-14. DOI: 10.1016/j.bpobgyn.2016.08.006. View

11.

Kaufman H, Taback B, Sherman W, Kim D, Shingler W, Moroziewicz D . Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med. 2009; 7:2. PMC: 2631474. DOI: 10.1186/1479-5876-7-2. View

12.

Stern P, Harrop R . 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer. Cancer Immunol Immunother. 2016; 66(4):415-426. PMC: 11029567. DOI: 10.1007/s00262-016-1917-3. View

13.

Giddabasappa A, Gupta V, Norberg R, Gupta P, Spilker M, Wentland J . Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular Tomography. Mol Cancer Ther. 2016; 15(10):2530-2540. DOI: 10.1158/1535-7163.MCT-15-1012. View

14.

Leal M, Wentland J, Han X, Zhang Y, Rago B, Duriga N . Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice. Bioconjug Chem. 2015; 26(11):2223-32. DOI: 10.1021/acs.bioconjchem.5b00205. View

15.

Testa U, Petrucci E, Pasquini L, Castelli G, Pelosi E . Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. Medicines (Basel). 2018; 5(1). PMC: 5874581. DOI: 10.3390/medicines5010016. View

16.

Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan M . Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res. 2006; 12(11 Pt 1):3416-24. DOI: 10.1158/1078-0432.CCR-05-2732. View

17.

Mulder W, Stern P, Stukart M, de Windt E, Butzelaar R, Meijer S . Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients. Clin Cancer Res. 1998; 3(11):1923-30. View

18.

Starzynska T, Marsh P, Schofield P, Roberts S, Myers K, Stern P . Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer. 1994; 69(5):899-902. PMC: 1968915. DOI: 10.1038/bjc.1994.173. View

19.

Zhang S, Yuan Y, Hao D . A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy. PLoS One. 2014; 9(12):e113169. PMC: 4249855. DOI: 10.1371/journal.pone.0113169. View

20.

Amato R, Hawkins R, Kaufman H, Thompson J, Tomczak P, Szczylik C . Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010; 16(22):5539-47. DOI: 10.1158/1078-0432.CCR-10-2082. View